Mind Medicine (MindMed) Inc. (MNMD)
NASDAQ: MNMD · IEX Real-Time Price · USD
8.68
-0.23 (-2.58%)
At close: Apr 19, 2024, 4:00 PM
8.66
-0.02 (-0.23%)
After-hours: Apr 19, 2024, 6:57 PM EDT
Company Description
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.
The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Mind Medicine (MindMed) Inc.
| Country | Canada |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Robert Barrow |
Contact Details
Address: One World Trade Center, Suite 8500 New York, New York 10007 United States | |
| Phone | 212-220-6633 |
| Website | mindmed.co |
Stock Details
| Ticker Symbol | MNMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001813814 |
| CUSIP Number | 60255C109 |
| ISIN Number | CA60255C8850 |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Robert Barrow | Chief Executive Officer and Director |
| Schond L. Greenway M.B.A. | Chief Financial Officer |
| Dr. Daniel Rollings Karlin M.A., M.D. | Chief Medical Officer |
| Dr. Miriam Halperin Wernli Ph.D. | Executive President |
| Dr. Scott M. Freeman M.D. | Co-Founder and Clinical Advisor |
| Leonard Latchman | Co-founder |
| Carrie F. Liao CPA, CGMA | Vice President and Chief Accounting Officer |
| Mark R. Sullivan J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Francois P. Lilienthal M.B.A., M.D. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 1, 2024 | 8-K | Current Report |
| Mar 25, 2024 | 144 | Filing |
| Mar 25, 2024 | 144 | Filing |
| Mar 21, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 18, 2024 | D | Notice of Exempt Offering of Securities |
| Mar 15, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 11, 2024 | 8-K | Current Report |
| Mar 8, 2024 | 424B5 | Filing |
| Mar 7, 2024 | 8-K | Current Report |